Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. Wang, J. , Iwasaki H. , Krivtsov A. , Febbo PG , Thorner AR , Ernst P. , Anastasiadou E. , Kutok JL , Kogan SC , Zinkel SS , Fisher JK , Hess JL , Golub T. R. , Armstrong SA , Akashi K. , and Korsmeyer SJ The EMBO journal, 2005/01/26, Volume 24, Issue 2, p.368-81, (2005)
Read More / View Supplemental Materials
Share This
(function(d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src = "//connect.facebook.net/en_US/all.js#xfbml=1";
fjs.parentNode.insertBefore(js, fjs);
}(document, 'script', 'facebook-jssdk'));
!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0];if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src="//platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");
(function() {
var po = document.createElement('script'); po.type = 'text/javascript'; po.async = true;
po.src = 'https://apis.google.com/js/plusone.js';
var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(po, s);
})();
Abstract